Inactive Instrument

Share ownership Galapagos NV Euronext Bruxelles

GLPG

BE0003818359

Biotechnology & Medical Research

End-of-day quote Euronext Bruxelles
-	-

08-12	Tranche Update on Lakefront Biotherapeutics NV's Equity Buyback Plan announced on June 9, 2026.	CI
08-11	RBC Adjusts PT on Lakefront Biotherapeutics to $26 From $28, Keeps Sector Perform Rating	MT

Share class: Galapagos NV

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	65,897,071	49,186,994 ( 74.64 %)	241,904 ( 0.3671 %)	74.64 %

Major shareholders: Galapagos NV

Name	Stocks	%	Valuation
GILEAD SCIENCES, INC. 25.35 %	16,707,477	25.35 %	459 M
EcoR1 Capital, LLC 10.92 %	7,193,777	10.92 %	197 M
Van Herk Investments BV 7.035 %	4,635,672	7.035 %	127 M
Niche Asset Management Ltd. 0.1017 %	67,000	0.1017 %	2 M
Saint Olive Gestion SNC 0.0645 %	42,500	0.0645 %	1 M
Zenito Oy 0.0493 %	32,500	0.0493 %	892 194
Ennismore Fund Management Ltd. 0.0167 %	11,000	0.0167 %	301 973
Mercer Global Investments Europe Ltd. 0.011 %	7,263	0.011 %	199 385
Universal Investment Luxembourg SA 0.007588 %	5,000	0.007588 %	137 261
Keyridge Asset Management Ltd. 0.006504 %	4,286	0.006504 %	117 660
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Stocks	%	Valuation
GILEAD SCIENCES, INC. 25.35 %	16,707,477	25.35 %	455 M
Tang Capital Management LLC 5.745 %	3,785,991	5.745 %	103 M
Madison Avenue Partners LP 5.472 %	3,606,203	5.472 %	98 M
Madison Avenue Partners LP 5.232 %	3,447,807	5.232 %	94 M
Prosight Management LP 3.101 %	2,043,344	3.101 %	56 M
EcoR1 Capital, LLC 2.53 %	1,667,119	2.53 %	45 M
Ameriprise Financial Services LLC 1.931 %	1,272,249	1.931 %	35 M
DME Capital Management LP 0.7326 %	482,746	0.7326 %	13 M
Renaissance Technologies LLC 0.6188 %	407,800	0.6188 %	11 M
Aperio Group LLC 0.4963 %	327,036	0.4963 %	9 M
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Gilead Sciences, Inc.	50.71%
Institutional	46.05%
Others	1.09%
Individuals	0.01%
Unknown	2.14%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	90.21%
Netherlands	7.03%
United Kingdom	0.17%
Norway	0.12%
France	0.07%
Canada	0.06%
Finland	0.05%
Monaco	0.04%
Germany	0.04%
Ireland	0.03%
Austria	0.02%
Luxembourg	0.01%
Individuals	0.01%

Based on 1000 largest holdings

Lakefront Biotherapeutics NV (formerly Galapagos NV) is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Lakefront Biotherapeutics NV prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas.

Employees

Sector

Biotechnology & Medical Research

Calendar

11-11 Earnings release - Q3 2026

More about the company